Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept for Bevacizumab-Resistant DME
NCT02924987Phase 4Unknown
- Sponsor
- Hôpital Maisonneuve-Rosemont
- Start
- Nov 2016
- Primary completion
- Nov 2017
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in diabetic macular edema (DME), sponsored by Hôpital Maisonneuve-Rosemont. Primary endpoint: Macular central subfield thickness at 6 months. Status: unknown.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02924987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02924987.